<em>TP53</em> loss‑of‑function mutations reduce sensitivity of acute leukaemia to the curaxin CBL0137

Forgione,Michelle O.; McClure,Barbara J.; Page,Elyse C.; Yeung,David T.; Eadie,Laura N.; White,Deborah L.

doi:10.3892/or.2022.8310

May-2022 Volume 47 Issue 5

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

May-2022 Volume 47 Issue 5

Full Size Image

Article

TP53 loss‑of‑function mutations reduce sensitivity of acute leukaemia to the curaxin CBL0137

Authors:
- Michelle O. Forgione
- Barbara J. McClure
- Elyse C. Page
- David T. Yeung
- Laura N. Eadie
- Deborah L. White
View Affiliations / Copyright

Affiliations: Cancer Program, Precision Medicine Theme, South Australian Health and Medical Research Institute (SAHMRI), Adelaide, South Australia 5000, Australia
Article Number: 99
|
Published online on: March 24, 2022

https://doi.org/10.3892/or.2022.8310
Expand metrics +

Abstract

The presence of a TP53 mutation is a predictor of poor outcome in leukaemia, and efficacious targeted therapies for these patients are lacking. The curaxin CBL0137 has demonstrated promising antitumour activities in multiple cancers such as glioblastoma, acting through p53 activation, NF‑κB inhibition and chromatin remodelling. In the present study, it was revealed using Annexin‑V/7‑AAD apoptosis assays that CBL0137 has efficacy across several human acute leukaemia cell lines with wild‑type TP53, but sensitivity is reduced in TP53‑mutated subtypes. A heterozygous TP53 loss‑of‑function mutation in the KMT2A‑AFF1 human RS4;11 cell line was generated, and it was demonstrated that heterozygous TP53 loss‑of‑function is sufficient to cause a significant reduction in CBL0137 sensitivity. To the best of our knowledge, this is the first evidence to suggest a clinically significant role for functional p53 in the efficacy of CBL0137 in acute leukaemia. Future CBL0137 clinical trials should include TP53 mutation screening, to establish the clinical relevance of TP53 mutations in CBL0137 efficacy.

View Figures

View References

1	Inaba H and Mullighan CG: Pediatric acute lymphoblastic leukemia. Haematologica. 105:2524–2539. 2020. View Article : Google Scholar : PubMed/NCBI
2	Shallis RM, Wang R, Davidoff A, Ma X and Zeidan AM: Epidemiology of acute myeloid leukemia: Recent progress and enduring challenges. Blood Rev. 36:70–87. 2019. View Article : Google Scholar : PubMed/NCBI
3	Stengel A, Kern W, Haferlach T, Meggendorfer M, Fasan A and Haferlach C: The impact of TP53 mutations and TP53 deletions on survival varies between AML, ALL, MDS and CLL: An analysis of 3307 cases. Leukemia. 31:705–711. 2017. View Article : Google Scholar : PubMed/NCBI
4	Stengel A, Schnittger S, Weissmann S, Kuznia S, Kern W, Kohlmann A, Haferlach T and Haferlach C: TP53 mutations occur in 15.7% of ALL and are associated with MYC-rearrangement, low hypodiploidy, and a poor prognosis. Blood. 124:251–258. 2014. View Article : Google Scholar : PubMed/NCBI
5	Kantidze OL, Luzhin AV, Nizovtseva EV, Safina A, Valieva ME, Golov AK, Velichko AK, Lyubitelev AV, Feofanov AV, Gurova KV, et al: The anti-cancer drugs curaxins target spatial genome organization. Nat Commun. 10:14412019. View Article : Google Scholar : PubMed/NCBI
6	Dallavalle S, Mattio LM, Artali R, Musso L, Aviñó A, Fàbrega C, Eritja R, Gargallo R and Mazzini S: Exploring the interaction of curaxin CBL0137 with G-quadruplex DNA oligomers. Int J Mol Sci. 22:64762021. View Article : Google Scholar : PubMed/NCBI
7	Gasparian AV, Burkhart CA, Purmal AA, Brodsky L, Pal M, Saranadasa M, Bosykh DA, Commane M, Guryanova OA, Pal S, et al: Curaxins: Anticancer compounds that simultaneously suppress NF-κB and activate p53 by targeting FACT. Sci Transl Med. 3:95ra742011. View Article : Google Scholar : PubMed/NCBI
8	Lock R, Carol H, Maris JM, Kolb EA, Gorlick R, Reynolds CP, Kang MH, Keir ST, Wu J, Purmal A, et al: Initial testing (stage 1) of the curaxin CBL0137 by the pediatric preclinical testing program. Pediatr Blood Cancer. 64:e262632017. View Article : Google Scholar : PubMed/NCBI
9	Somers K, Kosciolek A, Bongers A, El-Ayoubi A, Karsa M, Mayoh C, Wadham C, Middlemiss S, Neznanov N, Kees UR, et al: Potent antileukemic activity of curaxin CBL0137 against MLL-rearranged leukemia. Int J Cancer. 146:1902–1916. 2020. View Article : Google Scholar : PubMed/NCBI
10	Forgione MO, McClure BJ, Eadie LN, Yeung DT and White DL: KMT2A rearranged acute lymphoblastic leukaemia: Unravelling the genomic complexity and heterogeneity of this high-risk disease. Cancer Lett. 469:410–418. 2020. View Article : Google Scholar : PubMed/NCBI
11	Muntean AG and Hess JL: The pathogenesis of mixed-lineage leukemia. Annu Rev Pathol. 7:283–301. 2012. View Article : Google Scholar : PubMed/NCBI
12	Marks DI, Moorman AV, Chilton L, Paietta E, Enshaie A, DeWald G, Harrison CJ, Fielding AK, Foroni L, Goldstone AH, et al: The clinical characteristics, therapy and outcome of 85 adults with acute lymphoblastic leukemia and t(4;11)(q21;q23)/MLL-AFF1 prospectively treated in the UKALLXII/ECOG2993 trial. Haematologica. 98:945–952. 2013. View Article : Google Scholar : PubMed/NCBI
13	Aubrey BJ, Kelly GL, Kueh AJ, Brennan MS, O'Connor L, Milla L, Wilcox S, Tai L, Strasser A and Herold MJ: An inducible lentiviral guide RNA platform enables the identification of tumor-essential genes and tumor-promoting mutations in vivo. Cell Rep. 10:1422–1432. 2015. View Article : Google Scholar : PubMed/NCBI
14	Ralph P, Moore M and Nilsson K: Lysozyme synthesis by established human and murine histiocytic lymphoma cell lines. J Exp Med. 143:1528–1533. 1976. View Article : Google Scholar : PubMed/NCBI
15	Chanput W, Peters V and Wichers H: THP-1 and U937 cells. The Impact of Food Bioactives on Health. Verhoeckx K, Cotter P, López-Expósito I, Kleiveland C, Lea T, Mackie A, Requena T, Swiatecka D and Wichers H: Springer; Cham: pp. 147–159. 2015
16	Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, Wilson CJ, Lehár J, Kryukov GV, Sonkin D, et al: The cancer cell line encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 483:603–607. 2012. View Article : Google Scholar : PubMed/NCBI
17	Tate JG, Bamford S, Jubb HC, Sondka Z, Beare DM, Bindal N, Boutselakis H, Cole CG, Creatore C, Dawson E, et al: COSMIC: The catalogue of somatic mutations in cancer. Nucleic Acids Res. 47(D1): D941–D947. 2019. View Article : Google Scholar : PubMed/NCBI
18	Landrum MJ, Lee JM, Benson M, Brown GR, Chao C, Chitipiralla S, Gu B, Hart J, Hoffman D, Jang W, et al: ClinVar: Improving access to variant interpretations and supporting evidence. Nucleic Acids Res. 46(D1): D1062–D1067. 2018. View Article : Google Scholar : PubMed/NCBI
19	Zhang JD, Ruschhaupt M and Biczok R: ddCt method for qRT-PCR data analysis. Bioconductor. 2013.http://www.bioconductor.org/packages/release/bioc/vignettes/ddCt/inst/doc/rtPCR.pdfOctober 26–2021
20	He G, Siddik ZH, Huang Z, Wang R, Koomen J, Kobayashi R, Khokhar AR and Kuang J: Induction of p21 by p53 following DNA damage inhibits both Cdk4 and Cdk2 activities. Oncogene. 24:2929–2943. 2005. View Article : Google Scholar : PubMed/NCBI
21	Xia M, Knezevic D and Vassilev LT: p21 does not protect cancer cells from apoptosis induced by nongenotoxic p53 activation. Oncogene. 30:346–355. 2011. View Article : Google Scholar : PubMed/NCBI
22	Sarantopoulos J, Mahalingam D, Sharma N, Iyer RV, Ma WW, Ahluwalia MS, Johnson S, Purmal A, Shpigotskaya P, Hards A, et al: Results of a completed phase I trial of CBL0137 administered intravenously (IV) to patients (Pts) with advanced solid tumors. J Clin Oncol. 38 (Suppl 15):S35832020. View Article : Google Scholar
23	Fedyanin M, Tryakin A, Lisyanskaya AS, Solovyeva E, Fadeeva N, Gladkov O, Moiseyenko V, Cheporov SV, Shpigotskaya P, Purmal A, et al: Results of a completed first-in-human phase Ib dose-escalation study of oral CBL0137 in patients with advanced solid tumors. J Clin Oncol. 38 (Suppl 15):S36072020. View Article : Google Scholar
24	Chua MMJ, Lee M and Dominguez I: Cancer-type dependent expression of CK2 transcripts. PLoS One. 12:e01888542017. View Article : Google Scholar : PubMed/NCBI